Alimera Sciences (ALIM) Downgraded by ValuEngine to Strong Sell

ValuEngine lowered shares of Alimera Sciences (NASDAQ:ALIM) from a sell rating to a strong sell rating in a report issued on Sunday.

A number of other research analysts also recently commented on ALIM. HC Wainwright reaffirmed a buy rating and issued a $5.00 price target on shares of Alimera Sciences in a research note on Wednesday, November 22nd. Zacks Investment Research downgraded Alimera Sciences from a hold rating to a sell rating in a research note on Monday, November 27th. Finally, Cowen reaffirmed a buy rating on shares of Alimera Sciences in a research note on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $3.38.

Alimera Sciences (ALIM) remained flat at $$1.30 during mid-day trading on Friday. 90,100 shares of the stock were exchanged, compared to its average volume of 374,993. Alimera Sciences has a 52 week low of $1.04 and a 52 week high of $1.72. The company has a debt-to-equity ratio of -0.71, a current ratio of 4.84 and a quick ratio of 4.65.

Hedge funds and other institutional investors have recently modified their holdings of the business. KCG Holdings Inc. raised its stake in Alimera Sciences by 127.0% during the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 43,977 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Alimera Sciences by 24.3% during the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock worth $251,000 after acquiring an additional 35,200 shares in the last quarter. Stonepine Capital Management LLC raised its stake in Alimera Sciences by 158.2% during the third quarter. Stonepine Capital Management LLC now owns 477,226 shares of the biopharmaceutical company’s stock worth $644,000 after acquiring an additional 292,399 shares in the last quarter. Finally, JW Asset Management LLC raised its stake in Alimera Sciences by 15.6% during the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock worth $1,343,000 after acquiring an additional 130,000 shares in the last quarter. 41.85% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/04/alimera-sciences-alim-downgraded-by-valuengine-to-strong-sell.html.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply